Subscribe To
Crew aims to build the ‘hubspot for recruiting'
Amine Skalli recruited teams for ten years, including four as a tech professional recruiter. In her las...
February 14, 2023, 8:30 am
Kongsberg gruppen asa (nskff) q4 2022 earnings call transcript
Kongsberg Gruppen ASA (OTCPK:NSKFF) Q4 2022 Earnings Conference Call February 10, 2023 2:15 AM ET Company Participants Jan Erik - Vice President of In...
February 10, 2023, 10:52 am
Fluence energy, inc. (flnc) q1 2023 earnings call transcript
Fluence Energy, Inc. (NASDAQ:FLNC ) Q1 2023 Earnings Conference Call February 9, 2023 8:30 AM ET Company Participants Lexington May - Vice President, ...
February 9, 2023, 5:33 pm
Fluence energy, inc. (flnc) q4 2022 earnings call transcript
Fluence Energy, Inc. (NASDAQ:FLNC ) Q4 2022 Earnings Conference Call December 13, 2022 8:30 AM ET Company Participants Lexington May - VP, IR Julian N...
December 13, 2022, 7:04 pm
Avance gas holding ltd (avacf) q3 2022 earnings call transcript
Avance Gas Holding Ltd (OTCPK:AVACF) Q3 2022 Results Conference Call November 24, 2022 8:00 AM ET Company Participants Øystein ...
November 24, 2022, 11:51 am
Flex lng ltd. (flng) q3 2022 earnings call transcript
FLEX LNG Ltd. (NYSE:FLNG ) Q3 2022 Results Conference Call November 15, 2022 9:00 AM ET Company Participants Oystein ...
November 15, 2022, 1:55 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm
Intellia therapeutics presents new interim data from first-in-human study of ntla-2002 for the treatment of hereditary angioedema (hae) at the american college of allergy, asthma & immunology 2022 ann
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All pat...
November 12, 2022, 9:30 pm